Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) play an important role in alleviating pain, restoring function and improving quality of life in patients with chronic rheumatic diseases. Unfortunately, use of NSAIDs for long periods is associated with an increased risk of gastrointestinal adverse effects. Piroxicam-β-cyclodextrin is a new NSAID which is absorbed rapidly and thus achieves an early analgesic effect. A second potential advantage of more rapid absorption is that the drug is less likely to irritate the gastrointestinal mucosa and cause local adverse effects. Indeed, clinical studies of long term use of piroxicam-β-cyclodextrin have shown that this agent is at least as effective as other NSAIDs, with good gastrointestinal tolerability This favourable risk-benefit profile of piroxicam-β-cyclodextrin supports its use in the long term treatment of chronic rheumatic diseases.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
